Dr. Reddy's surges on getting USFDA’s nod for migraine treatment oral solution

07 May 2020 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 3936.35, up by 79.60 points or 2.06% from its previous closing of Rs. 3856.75 on the BSE.

The scrip opened at Rs. 3888.00 and has touched a high and low of Rs. 3936.35 and Rs. 3885.10 respectively. So far 219 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4095.00 on 22-Apr-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 4004.55 and Rs. 3805.95 respectively. The current market cap of the company is Rs. 64088.42 crore.

The promoters holding in the company stood at 26.76% while Institutions and Non-Institutions held 45.14% and 13.80% respectively.

Dr. Reddy's Laboratories and its subsidiaries have received approval for their NDA, Elyxyb (celecoxib oral solution 25 mg/mL) from the US Food and Drug Administration (USFDA).

ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults. ELYXYB is the latest product emerging from Dr. Reddy's portfolio of successful acute migraine treatments. The company is working to commercialize this product through partners.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1212.50 4.05 (0.34%)
30-Jan-2026 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1592.40
Dr. Reddys Lab 1212.50
Cipla 1321.15
Zydus Lifesciences 891.00
Lupin 2153.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×